Non-invasive VNS Effects on Hyperarousal and Autonomic State in Patients with PTSD
science
Trial
Results
Patients in our pilot study were some of the first to wear the Phoenix® and experience the relief it can provide.
Find the results from our pilot study below.
PILOT TRIAL RESULTS
PTSD
The FDA requires a 50% responder rate and an average 6 pt reduction in the CAPS-5.
The Phoenix exceeded these requirements and provided an average 18.4 pt reduction in CAPS-5, with only 1 non-responder and 1 non-compliant participant. These results were statistically and clinically significant with a p-value of .0100 and a 95%CI: 0.57, 0.98.
Quality of Life
The Promis-29 looks at 7 aspects of quality of life and compares responses to the general population to determine severity of responses.
Clinical research
Clinical Research
Support
-
Assist with protocol development
-
Full training and installation
-
Clinical support
-
IT support for data collection, download and interpretation
-
Repair, maintenance and replacement
“What do I have to lose? It’s not a drug that I’m putting in my system and its not something that I’m smoking. So, if you’re telling me that you can put something in my ear and make me better, sign me up every day of the week!”
-Pilot Study Participant